Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002920 · ClinicalTrials.gov registry record · Phase 3
S9630, Medroxyprogesterone in Treating Women With Breast Cancer
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 313
- Enrollment target
NCT00002920: Completed Phase 3 study, sponsored by SWOG Cancer Research Network.
NCT00002920 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 313 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002920, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 313 participants
- Enrollment target
Study Summary
RATIONALE: It is not yet known whether medroxyprogesterone is effective in preventing endometrial disorder in patients with breast cancer who are taking tamoxifen. PURPOSE: Randomized phase III trial to study the effectiveness of medroxyprogesterone in preventing endometrial disorder in postmenopausal women who have ductal carcinoma in situ, lobular carcinoma in situ, Paget's disease of the nipple, stage I breast cancer, or stage II breast cancer and who are taking tamoxifen.
Primary Outcome
Endometrial pathologic diagnosis at 2 years after registration
Interventions
- PROCEDURE adjuvant therapy
- DRUG tamoxifen citrate
- DRUG medroxyprogesterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 1997-03 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
What the finished NCT00002920 record still lists
NCT00002920 is an interventional study that assigns participants to a tested intervention. The registered 313 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 3 interventions - of which adjuvant therapy is the first listed.
NCT00002920 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002920 about?
NCT00002920 is a clinical study titled "S9630, Medroxyprogesterone in Treating Women With Breast Cancer". RATIONALE: It is not yet known whether medroxyprogesterone is effective in preventing endometrial disorder in patients with breast cancer who are taking tamoxifen. PURPOSE: Randomized phase III trial to study the effectiveness of medroxyprogesterone in preventing endometrial disorder in postmenopau...
What is the current status of trial NCT00002920?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 313 participants. The study started on 1997-03. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00002920?
The interventions under investigation include: adjuvant therapy (PROCEDURE), tamoxifen citrate (DRUG), medroxyprogesterone (DRUG).
Who is sponsoring clinical trial NCT00002920?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002920's enrollment target sits among peer trials
313 1101st of 2000 higher than 899 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00595491 · 313 participants · Phase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia